0000950170-23-063927.txt : 20231114
0000950170-23-063927.hdr.sgml : 20231114
20231114192302
ACCESSION NUMBER: 0000950170-23-063927
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231110
FILED AS OF DATE: 20231114
DATE AS OF CHANGE: 20231114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brennan Aoife
CENTRAL INDEX KEY: 0001714563
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37566
FILM NUMBER: 231408622
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET, SUITE 320
STREET 2: C/O SYNLOGIC, INC.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SYNLOGIC, INC.
CENTRAL INDEX KEY: 0001527599
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261824804
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-401-9975
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
STREET 2: SUITE 402
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Mirna Therapeutics, Inc.
DATE OF NAME CHANGE: 20110809
4
1
ownership.xml
4
X0508
4
2023-11-10
0001527599
SYNLOGIC, INC.
SYBX
0001714563
Brennan Aoife
C/O SYNLOGIC, INC.
301 BINNEY STREET, SUITE 402
CAMBRIDGE
MA
02142
true
true
President and CEO
false
Stock Option (right to buy)
202.95
2023-11-10
4
D
false
5591
D
2027-05-15
Common Stock
5591
0
D
Stock Option (right to buy)
149.25
2023-11-10
4
D
false
3733
D
2028-03-14
Common Stock
3733
0
D
Stock Option (right to buy)
143.25
2023-11-10
4
D
false
3600
D
2028-06-05
Common Stock
3600
0
D
Stock Option (right to buy)
118.65
2023-11-10
4
D
false
9999
D
2028-10-31
Common Stock
9999
0
D
Stock Option (right to buy)
128.85
2023-11-10
4
D
false
12332
D
2029-03-05
Common Stock
12332
0
D
Stock Option (right to buy)
25.50
2023-11-10
4
D
false
12352
D
2030-03-10
Common Stock
12352
0
D
Stock Option (right to buy)
52.50
2023-11-10
4
D
false
18999
D
2031-03-10
Common Stock
18999
0
D
Stock Option (right to buy)
29.25
2023-11-10
4
D
false
28943
D
2032-02-04
Common Stock
28943
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
42999
D
2033-03-16
Common Stock
42999
0
D
Stock Option (right to buy)
9.30
2023-11-10
4
D
false
8666
D
2033-03-16
Common Stock
8666
0
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
5591
A
2027-05-15
Common Stock
5591
5591
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
3733
A
2028-03-14
Common Stock
3733
3733
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
3600
A
2028-06-05
Common Stock
3600
3600
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
9999
A
2028-10-31
Common Stock
9999
9999
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
12332
A
2029-03-05
Common Stock
12332
12332
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
12352
A
2030-03-10
Common Stock
12352
12352
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
18999
A
2031-03-10
Common Stock
18999
18999
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
28943
A
2032-02-04
Common Stock
28943
28943
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
42999
A
2033-03-16
Common Stock
42999
42999
D
Stock Option (right to buy)
1.85
2023-11-10
4
A
false
8666
A
2033-03-16
Common Stock
8666
8666
D
In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
The shares subject to this option are fully vested as of the date hereof.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.
/s/ Aoife Brennan
2023-11-14